Literature DB >> 10516852

Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer.

R I Nicholson1, R A McClelland, J F Robertson, J M Gee.   

Abstract

Multiple lines of evidence implicate steroid hormone and growth factor cross-talk as a modulator of endocrine response in breast cancer and that aberrations in growth factor signaling pathways are a common element in the endocrine resistant phenotype. Delineation of these relationships is thus an important diagnostic goal in cancer research, while the targeting of aberrant growth factor signaling holds the promise of improving therapeutic response rates.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10516852     DOI： 10.1677/erc.0.0060373

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN： 1351-0088            Impact factor:   5.678


  23 in total

Review 1.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

2.  Epidermal growth factor receptor and tyrosine phosphorylation of estrogen receptor.

Authors:  D C Márquez; J Lee; T Lin; R J Pietras
Journal:  Endocrine       Date:  2001-11       Impact factor: 3.633

3.  Metastasis-associated protein 2 is a repressor of estrogen receptor alpha whose overexpression leads to estrogen-independent growth of human breast cancer cells.

Authors:  Yukun Cui; Airu Niu; Richard Pestell; Rakesh Kumar; Edward M Curran; Yunde Liu; Suzanne A W Fuqua
Journal:  Mol Endocrinol       Date:  2006-04-27

4.  Estrogen receptors and proliferation markers in primary and recurrent breast cancer.

Authors:  E V Jensen; G Cheng; C Palmieri; S Saji; S Mäkelä; S Van Noorden; T Wahlström; M Warner; R C Coombes; J A Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-04       Impact factor: 11.205

5.  Gefitinib or placebo in combination with tamoxifen in patients with hormone receptor-positive metastatic breast cancer: a randomized phase II study.

Authors:  C Kent Osborne; Patrick Neven; Luc Y Dirix; John R Mackey; Jean Robert; Craig Underhill; Rachel Schiff; Carolina Gutierrez; Ilenia Migliaccio; Valsamo K Anagnostou; David L Rimm; Patrick Magill; Mark Sellers
Journal:  Clin Cancer Res       Date:  2011-01-10       Impact factor: 12.531

6.  Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications.

Authors:  Wilko Weichert; Glen Kristiansen; Klaus-Jürgen Winzer; Mathias Schmidt; Volker Gekeler; Aurelia Noske; Berit-Maria Müller; Silvia Niesporek; Manfred Dietel; Carsten Denkert
Journal:  Virchows Arch       Date:  2005-03-23       Impact factor: 4.064

Review 7.  Chemoprevention of breast cancer: implications for postmenopausal women.

Authors:  Carol J Fabian; Bruce F Kimler
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

8.  Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.

Authors:  Cynthie Wong; Shiuan Chen
Journal:  Cancer Res       Date:  2009-10-27       Impact factor: 12.701

9.  Growth factor-induced resistance to tamoxifen is associated with a mutation of estrogen receptor alpha and its phosphorylation at serine 305.

Authors:  Cinzia Giordano; Yukun Cui; Ines Barone; Sebastiano Ando; Michael A Mancini; Valeria Berno; Suzanne A W Fuqua
Journal:  Breast Cancer Res Treat       Date:  2009-02-11       Impact factor: 4.872

10.  Tristetraprolin represses estrogen receptor α transactivation in breast cancer cells.

Authors:  Tonatiuh Barrios-García; Angeles Tecalco-Cruz; Vania Gómez-Romero; Sandra Reyes-Carmona; Iván Meneses-Morales; Alfonso León-Del-Río
Journal:  J Biol Chem       Date:  2014-04-15       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.